ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,040.53
-0.50%
US Tech 100
20,778.00
-0.69%
다우존스 지수
44,544.66
-0.75%
Bitcoin
100,855.45
0.19%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Atossa Therapeutics Inc (ATOS) 시세

Atossa Therapeutics Inc

Atossa Therapeutics Inc (ATOS)

NASDAQ
0.8419
-0.0234
(-2.70%)
마감 02 2월 6:00AM
15분 지연
0.8201
-0.0218
(-2.59%)
시간외 거래: 9:40AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
0.8201
매수가
0.82
매도가
4.00
거래량
722,452
0.8299 일간 변동폭 0.9179
0.7203 52주 범위 2.31
market_cap
103.17M
전일 종가
0.8653
개장가
0.87
최근 거래 시간
4
@
0.8599
마지막 거래 시간
재정 규모
US$ 630,853
VWAP
0.873211
평균 볼륨(3m)
905,318
발행 주식
125,801,254
배당수익률
-
주가수익률
-3.51
주당순이익(EPS)
-0.24
매출
-
순이익
-30.09M

Atossa Therapeutics Inc 정보

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.atossatherapeutics.com
본부
Wilmington, Delaware, USA
설립됨
-
Atossa Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker ATOS. The last closing price for Atossa Therapeutics was US$0.87. Over the last year, Atossa Therapeutics shares have traded in a share price range of US$ 0.7203 to US$ 2.31.

Atossa Therapeutics currently has 125,801,254 shares in issue. The market capitalisation of Atossa Therapeutics is US$108.86 million. Atossa Therapeutics has a price to earnings ratio (PE ratio) of -3.51.

ATOS 최신 뉴스

추가 뉴스

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

30 1월 2025
GlobeNewswire Inc.

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

23 1월 2025
GlobeNewswire Inc.

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

06 1월 2025
GlobeNewswire Inc.

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

12 12월 2024
GlobeNewswire Inc.

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session...

11 12월 2024
GlobeNewswire Inc.

Form 8-K - Current report

10 12월 2024
Edgar (US Regulatory)

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

10 12월 2024
GlobeNewswire Inc.

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

SEATTLE, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

09 12월 2024
GlobeNewswire Inc.

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that a poster detailing the anti-cancer activity of...

21 11월 2024
GlobeNewswire Inc.

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

20 11월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.1099-11.81720430110.930.970.72037926850.87458321CS
4-0.1689-17.07785642060.9891.040.72038303630.89568254CS
12-0.6699-44.95973154361.491.660.72039053181.09976417CS
26-0.5699-411.391.660.72036933971.22509247CS
52-0.0209-2.485136741970.8412.310.720310304051.41299611CS
156-0.4099-33.3252032521.232.310.58999371.18189219CS
260-0.6299-43.44137931031.459.80.535765123.14762667CS

ATOS - Frequently Asked Questions (FAQ)

What is the current Atossa Therapeutics share price?
The current share price of Atossa Therapeutics is US$ 0.8201
How many Atossa Therapeutics shares are in issue?
Atossa Therapeutics has 125,801,254 shares in issue
What is the market cap of Atossa Therapeutics?
The market capitalisation of Atossa Therapeutics is USD 108.86M
What is the 1 year trading range for Atossa Therapeutics share price?
Atossa Therapeutics has traded in the range of US$ 0.7203 to US$ 2.31 during the past year
What is the PE ratio of Atossa Therapeutics?
The price to earnings ratio of Atossa Therapeutics is -3.51
What is the reporting currency for Atossa Therapeutics?
Atossa Therapeutics reports financial results in USD
What is the latest annual profit for Atossa Therapeutics?
The latest annual profit of Atossa Therapeutics is USD -30.09M
What is the registered address of Atossa Therapeutics?
The registered address for Atossa Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Atossa Therapeutics website address?
The website address for Atossa Therapeutics is www.atossatherapeutics.com
Which industry sector does Atossa Therapeutics operate in?
Atossa Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
731.1M
REBNReborn Coffee Inc
US$ 3.31
(63.05%)
55.54M
FCUVFocus Universal Inc
US$ 5.87
(56.62%)
1.73M
SOPASociety Pass Inc
US$ 1.54
(56.50%)
13.87M
CYCNCyclerion Therapeutics Inc
US$ 3.92
(54.33%)
82.57M
ENVBEnveric Biosciences Inc
US$ 2.0899
(-46.41%)
1.57M
NIVFNewGenIvf Group Ltd
US$ 0.1489
(-42.51%)
14.8M
GLSTGlobal Star Acquisition Inc
US$ 8.83
(-39.10%)
23.89k
PRPHProPhase Labs Inc
US$ 0.2633
(-38.02%)
872.46k
SPGCSacks Parente Golf Inc
US$ 0.5601
(-37.86%)
7.27M
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
729.72M
NVDANVIDIA Corporation
US$ 120.07
(-3.67%)
388.54M
RIMEAlgorhythm Holdings Inc
US$ 0.02565
(5.12%)
338.75M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0355
(-11.25%)
236.29M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1938
(30.77%)
234.8M

ATOS Discussion

게시물 보기
eb0783 eb0783 1 주 전
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025.

https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-issues-letter-shareholders-highlighting-2024
👍️0
glenn1919 glenn1919 1 주 전
ATOS.........................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
XenaLives XenaLives 5 월 전
Why on earth did it take me so long to find this?



Following...

https://x.com/stevenquay
👍️0
XenaLives XenaLives 5 월 전
I think I'm in love... LOL!!!



Historical perspective:

👍️0
XenaLives XenaLives 5 월 전
More interesting...

https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
XenaLives XenaLives 5 월 전
ATOS chart...

👍️0
XenaLives XenaLives 5 월 전
Interesting .. also from Google...

A response to this query...

what is unique about atossa therapeutics inc

Response...

Is Atossa Therapeutics a good buy?
Why is Atossa stock dropping?
Who owns Atossa Therapeutics?
What is the target price for Atossa Genetics?
Stock Price Target ATOS
High $6.25
Median $6.00
Low $4.00
Average $5.42
Current Price $1.39

ATOS | Atossa Therapeutics Inc. Analyst Estimates & Rating - WSJ

WSJ
https://www.wsj.com › quotes › ATOS › research-ratings
Search for: What is the target price for Atossa Genetics?
What is the stock price forecast for Atossa Therapeutics in 2025?
What does Atossa Therapeutics do?


👍️0
XenaLives XenaLives 5 월 전
From Google Generative AI:


Atossa Therapeutics is a clinical-stage biopharmaceutical company that develops innovative medicines for oncology, with a focus on breast cancer and other breast conditions. Some unique aspects of Atossa Therapeutics include:
Patented (Z)-endoxifen
Atossa has patented the chemical process and composition of matter for (Z)-endoxifen, as well as a patented oral enteric capsule formulation.
Phase 2 I-SPY 2 Clinical Trial
Atossa is fully enrolling this trial, which is evaluating (Z)-endoxifen as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive breast cancer.
Phase 2 trials
Atossa is currently studying (Z)-endoxifen in four Phase 2 trials, including one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and two other studies.
U.S. patents
Atossa's (Z)-endoxifen is protected by three issued U.S. patents and numerous pending patent applications.
👍️0
XenaLives XenaLives 5 월 전
Intriguing science...
👍️0
XenaLives XenaLives 5 월 전

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-00701&r=1
👍️0
XenaLives XenaLives 5 월 전
Link to Atossa pipeline...
https://atossatherapeutics.com/product-pipeline/
👍️0
XenaLives XenaLives 5 월 전
Following - some valid science is going on here...
👍️0
glenn1919 glenn1919 6 월 전
ATOS....................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 월 전
ATOS.........................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 월 전
ATOS...............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 9 월 전
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️ 1
Joeyohso Joeyohso 10 월 전
Also no debt and 90m+ in cash. That is unheard of for a research pharma company. They also are extending the employee stock purchase program for all of 2024. This stock is a gem
👍️0
ShadowDiviner72 ShadowDiviner72 10 월 전
New PR, and data release shows that Endoxifen does not only stop the tumor from growing...

It even shows that it eliminates the tumor !!!!!! They cured a patient from breast cancer by taking a simple pill during 6 months!

INCREDIBLE
👍️0
glenn1919 glenn1919 10 월 전
ATOS...........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Joeyohso Joeyohso 10 월 전
Why the dump today? I was able to grab some at 1.65
👍️0
Monksdream Monksdream 10 월 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 10 월 전
ATOS new 52 hi
👍️0
Monksdream Monksdream 10 월 전
ATOS 10Q due 4/5
👍️0
Monksdream Monksdream 10 월 전
ATOS new 52 hi
👍️0
glenn1919 glenn1919 10 월 전
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 10 월 전
ATOS..LEVEL 2 LOOKING VERY NICE IN PRE
👍️0
TrendTrade2016 TrendTrade2016 10 월 전
ATOS...GET READY TO RUMBLE...WE ARE LOCKED IN AND LOADED TO 1.73
👍️0
glenn1919 glenn1919 11 월 전
ATOS.............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 11 월 전
ATOS.........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 11 월 전
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 년 전
ATOS................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Birdbrain Ideas Birdbrain Ideas 1 년 전
There hasn't been a post on this board in six weeks. If these Stage 2 trials turn out well, this board will light up along with the share price.
👍️0
Laster Laster 2 년 전
I loved that wall at $1.04 yesterday. It was calling my name. I was too slow.
Then it was taken out. I wasn’t too upset because….
I was lucky enough for another wall at $1.05 that I helped take out. Then boom.
Chart looked good. News good. Repurchase plan news excellent.
What’s not to like.
Hope to see if move back above $2.
Good luck.
👍️0
tw0122 tw0122 2 년 전
Looking good. Hidden gem not any longer
👍️0
killrEngineer killrEngineer 2 년 전
Wow. No comments?
10 million share repurchase announcement yesterday and study enrollment announcement today.
👍️0
DrJinx DrJinx 2 년 전
This aged like milk. How's that priming for a big run up working out for you? Maybe someday people will realize the company is smoke and mirrors. Keep in mind your CEO is old as F, he dies... this thing tanks even harder.
👍️0
Engle1488 Engle1488 3 년 전
We are primed for a big run up people. In at 1.04
👍️0
Agreed Agreed 3 년 전
The market cap is less than their holdings in cash...clearly undervalued.
👍️0
Agreed Agreed 3 년 전
Insider buying by CEO and CFO, new patent protections...looking promising.
👍️0
DollarSquad DollarSquad 3 년 전
Yes. You likely lost a lot of money. This investment is worthless. RMSL
👍️0
4MVault 4MVault 3 년 전
Did something just happen?
👍️0
slugo1 slugo1 3 년 전
Looking for bottom here
👍️0
ttottip ttottip 3 년 전
Yes, very soon. This will reverse the trend.
👍️0
slugo1 slugo1 3 년 전
Soon
👍️0
ttottip ttottip 3 년 전
Soon the 2.5's , 2.6's .....
👍️0
slugo1 slugo1 3 년 전
Yes
👍️0
ttottip ttottip 3 년 전
The 2.6's on the horizon.
👍️0
slugo1 slugo1 3 년 전
That's one of the things I like about them Also there should be some updates coming
👍️0
ttottip ttottip 3 년 전
140 millions of dollars cash? ATOS can do great things with this money.
👍️0
slugo1 slugo1 3 년 전
Nice buy worth alot when this hits $10.00
👍️0

최근 히스토리

NASDAQ
ATOS
Atossa Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지